| Primary |
|
| Neutropenic Sepsis |
50.0% |
| Pyrexia |
50.0% |
|
| Secondary |
| Product Used For Unknown Indication |
14.4% |
| Pancreatic Carcinoma Metastatic |
13.4% |
| Infection |
10.1% |
| Drug Use For Unknown Indication |
8.9% |
| Neutropenic Sepsis |
6.6% |
| Antibiotic Prophylaxis |
6.5% |
| Pneumonia |
4.5% |
| Abdominal Infection |
4.2% |
| Pyrexia |
4.2% |
| Pneumonia Aspiration |
4.0% |
| Prophylaxis |
3.7% |
| Cellulitis |
3.1% |
| Urinary Tract Infection |
3.1% |
| Pseudomonas Infection |
2.7% |
| Sedation |
2.3% |
| Staphylococcal Infection |
2.0% |
| Septic Shock |
1.8% |
| Lower Respiratory Tract Infection |
1.6% |
| Antibiotic Therapy |
1.5% |
| Febrile Neutropenia |
1.5% |
|
| Thrombocytopenia |
20.2% |
| Platelet Count Decreased |
13.1% |
| Toxic Epidermal Necrolysis |
6.6% |
| Death |
5.6% |
| White Blood Cell Count Increased |
5.6% |
| Septic Shock |
5.1% |
| Vomiting |
5.1% |
| Rash Pustular |
4.0% |
| Stevens-johnson Syndrome |
4.0% |
| White Blood Cell Count Decreased |
4.0% |
| Intraocular Pressure Increased |
3.5% |
| Rash Maculo-papular |
3.5% |
| Clostridium Difficile Infection |
2.5% |
| Nausea |
2.5% |
| Neutropenia |
2.5% |
| Pancytopenia |
2.5% |
| Pyrexia |
2.5% |
| Rash |
2.5% |
| Skin Exfoliation |
2.5% |
| Anaphylactic Reaction |
2.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
30.5% |
| Infection Prophylaxis |
10.2% |
| Prophylaxis |
8.6% |
| Pneumonia |
6.1% |
| Drug Use For Unknown Indication |
5.5% |
| Bone Marrow Conditioning Regimen |
4.9% |
| Acute Myeloid Leukaemia |
4.5% |
| Prophylaxis Against Graft Versus Host Disease |
4.2% |
| Infection |
3.7% |
| Sepsis |
2.7% |
| Antifungal Prophylaxis |
2.5% |
| Premedication |
2.3% |
| Prophylaxis Of Nausea And Vomiting |
2.2% |
| Acute Lymphocytic Leukaemia |
2.2% |
| Pyrexia |
2.0% |
| Febrile Neutropenia |
1.9% |
| Analgesic Therapy |
1.6% |
| Antibiotic Prophylaxis |
1.6% |
| Aplastic Anaemia |
1.5% |
| Pain |
1.3% |
|
| Septic Shock |
11.6% |
| Sepsis |
9.8% |
| Pyrexia |
7.7% |
| Death |
7.4% |
| Respiratory Failure |
6.8% |
| White Blood Cell Count Decreased |
6.8% |
| Thrombocytopenia |
6.3% |
| Renal Failure Acute |
6.0% |
| Pneumonia |
5.4% |
| Toxic Epidermal Necrolysis |
4.5% |
| Hepatic Function Abnormal |
3.6% |
| Vomiting |
3.3% |
| Platelet Count Decreased |
3.0% |
| Febrile Neutropenia |
2.7% |
| Pancytopenia |
2.7% |
| Rash |
2.7% |
| Rhabdomyolysis |
2.7% |
| Drug Ineffective |
2.4% |
| International Normalised Ratio Increased |
2.4% |
| Renal Impairment |
2.4% |
|
| Interacting |
| Periorbital Cellulitis |
45.5% |
| Chest Pain |
20.5% |
| Pulmonary Embolism |
10.2% |
| Chalazion |
4.5% |
| Osteomyelitis |
3.4% |
| Staphylococcal Sepsis |
3.4% |
| Bacterial Infection |
2.3% |
| Erysipelas |
2.3% |
| Myoclonic Epilepsy |
2.3% |
| Aplastic Anaemia |
1.1% |
| Cellulitis |
1.1% |
| Embolism |
1.1% |
| Herpes Zoster |
1.1% |
| Hyperpyrexia |
1.1% |
|
| Pyrexia |
44.4% |
| Drug Interaction |
11.1% |
| Intraocular Pressure Increased |
11.1% |
| Hepatitis Cholestatic |
5.6% |
| International Normalised Ratio Increased |
5.6% |
| Nephritis |
5.6% |
| Pancytopenia |
5.6% |
| Rash Papular |
5.6% |
| Staphylococcal Sepsis |
5.6% |
|
